Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.69 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13874987 | 0.91 | DYRK1A (0.82) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL2217485 | 0.83 | DYRK1A (0.80) | DYRK1AACHEHASPINHTR2AHTR2C | |
| SCHEMBL20340616 | 0.83 | DYRK1A (0.88) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL668477 | 0.82 | DYRK1A (1.00) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL2215202 | 0.81 | DYRK1A (0.81) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL21393533 | 0.81 | DYRK1A (0.80) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL17517503 | 0.81 | DYRK1A (0.88) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL13875060 | 0.81 | HASPIN (0.88) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL28590131 | 0.81 | DYRK1A (0.79) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL13494641 | 0.81 | DYRK1A (0.66) | DYRK1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | BRCA1, CA7, DCK | DYRK1A 2258/4885MAOA 3499/4885ACHE 1317/4885 |
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | BRCA1, CA7, DCK | DYRK1A 2229/4885MAOA 3791/4885ACHE 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.